Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
74
GOSS Quote, Financials, Valuation and Earnings
Last price:
$1.72
Seasonality move
:
3.89%
Day range:
$1.47 - $1.70
52-week range:
$0.66 - $1.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.06x
P/B ratio:
8.01x
Volume:
4.2M
Avg. volume:
2.4M
1-year change:
32.8%
Market cap:
$377.3M
Revenue:
$114.7M
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.03, Gossamer Bio has an estimated upside of 383.81% from its current price of $1.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.25 representing 24.7% downside risk from its current price of $1.66.
Fair Value
-
According to the consensus of 6 analysts, Gossamer Bio has 383.81% upside to fair value with a price target of $8.03 per share.
GOSS vs. S&P 500
-
Over the past 5 trading days, Gossamer Bio has overperformed the S&P 500 by 21.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Gossamer Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gossamer Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Gossamer Bio reported revenues of $9.9M.
Earnings Growth
-
Gossamer Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Gossamer Bio reported earnings per share of -$0.16.
Enterprise value:
317.2M
EV / Invested capital:
--
Price / LTM sales:
3.06x
EV / EBIT:
--
EV / Revenue:
2.55x
PEG ratio (5yr expected):
--
EV / Free cash flow:
34.91x
Price / Operating cash flow:
41.95x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-15.52%
Net Income Margin (TTM):
-41.13%
Return On Equity:
-138.01%
Return On Invested Capital:
-21.61%
Operating Margin:
-372.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $124.6M | -- | $9.9M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$212.1M | -$167.8M | -$54.8M | -$42M | -$36.8M | |
| EBITDA | -$202.4M | -$155.2M | -$35.7M | -$37.8M | -$33.6M | |
| Diluted EPS | -$2.50 | -$1.00 | -$0.23 | -$0.19 | -$0.16 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $465.8M | $280.8M | $210.4M | $255.3M | $275.5M | |
| Total Assets | $482.5M | $294.7M | $219.9M | $259.4M | $280.6M | |
| Current Liabilities | $29.4M | $34.6M | $40.6M | $35.8M | $48.2M | |
| Total Liabilities | $210.4M | $264.5M | $248.4M | $232.6M | $286.8M | |
| Total Equity | $272.1M | $30.2M | -$28.5M | $26.7M | -$6.3M | |
| Total Debt | -- | -- | -- | -- | $197.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$186.5M | -$158.5M | $9.1M | -$52.3M | -$39.7M | |
| Cash From Investing | -$733K | -$58M | -$10.6M | $61.7M | $22.1M | |
| Cash From Financing | $113.8M | $190.1M | -$8.4M | -$2.6M | $504K | |
| Free Cash Flow | -$186.9M | -$158.5M | $9.1M | -$52.3M | -$39.8M | |
GOSS
Sector
Market Cap
$377.3M
$34.4M
Price % of 52-Week High
97.65%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
32.8%
-37.36%
Beta (5-Year)
1.861
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.41
200-day SMA
Buy
Level
$1.05
Bollinger Bands (100)
Buy
Level
0.98 - 1.36
Chaikin Money Flow
Buy
Level
7.2M
20-day SMA
Buy
Level
$1.34
Relative Strength Index (RSI14)
Buy
Level
71.47
ADX Line
Buy
Level
40.47
Williams %R
Sell
Level
-7.9208
50-day SMA
Buy
Level
$1.24
MACD (12, 26)
Buy
Level
0.41
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
8.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2924)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Stock Forecast FAQ
In the current month, GOSS has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The GOSS average analyst price target in the past 3 months is $8.03.
-
Where Will Gossamer Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gossamer Bio share price will rise to $8.03 per share over the next 12 months.
-
What Do Analysts Say About Gossamer Bio?
Analysts are divided on their view about Gossamer Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gossamer Bio is a Sell and believe this share price will drop from its current level to $1.25.
-
What Is Gossamer Bio's Price Target?
The price target for Gossamer Bio over the next 1-year time period is forecast to be $8.03 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is GOSS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gossamer Bio is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GOSS?
You can purchase shares of Gossamer Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gossamer Bio shares.
-
What Is The Gossamer Bio Share Price Today?
Gossamer Bio was last trading at $1.72 per share. This represents the most recent stock quote for Gossamer Bio. Yesterday, Gossamer Bio closed at $1.66 per share.
-
How To Buy Gossamer Bio Stock Online?
In order to purchase Gossamer Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
